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Background: Cyclooxygenase (COX)-2 inhibitors including celecoxib are as effective as non-selective non-steroidal
anti-inflammatory drugs (ns-NSAIDs) in the treatment of osteoarthritis (OA) and have less gastrointestinal toxicity.
Although they are associated with higher treatment costs, COX-2 inhibitors may simultaneously reduce costs
associated with adverse events, hence, their overall economic benefit should be assessed.
Objective: To evaluate the incremental cost effectiveness ratio (ICER) of celecoxib versus ns-NSAIDs, with/without
proton-pump inhibitor (PPI) co-therapy, for managing OA in Saudi Arabian subjects aged ≥65 years.
Methods: The National Institute for Health and Care Excellence health economic model from the UK, updated with
relative risks of adverse events using CONDOR trial data, was adapted. Patients received celecoxib or ns-NSAIDs,
with/without omeprazole. The effectiveness measure was quality-adjusted life years (QALYs) gained per patient. The
analysis was conducted from the patient’s perspective. Frequencies of resource use for adverse events were based
on data collected in July 2012 from seven private hospitals in Jeddah, Saudi Arabia. Probabilistic sensitivity analysis
was performed to construct cost-effectiveness acceptability curves (CEACs).
Results: Over a 6-month treatment duration, QALYs gained per patient were higher with celecoxib (0.37) and
celecoxib plus PPI (0.40) versus comparators. Ibuprofen plus PPI showed the lowest expected cost per patient (US$
1,314.50 versus US$ 1,422.80 with celecoxib plus PPI and US$ 1,543.50 with celecoxib). Celecoxib plus PPI was the
most cost-effective option with an ICER of US$ 1,805.00, followed by celecoxib (ICER, US$ 7,633.33) versus ibuprofen
plus PPI. Over 2- and 5-year treatment durations, celecoxib plus PPI, and celecoxib, showed higher QALYs gained/
patient and lower ICERs versus comparators. These ICERs are <1 gross domestic product/capita in Saudi Arabia in
2013 (US$ 25,961).
CEACs over 6 months’ treatment showed a significantly higher likelihood that celecoxib plus PPI and celecoxib
alone would be more cost effective versus comparators once the willingness to pay is over US$ 2,000.00.
Conclusion: After considering new adverse event risks, celecoxib with/without PPI co-therapy was deemed very
cost effective for medium- and long-term use in Saudi Arabian OA patients aged ≥65 years.
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Osteoarthritis (OA) is a widely prevalent condition, which is
associated with significant morbidity and quality-of-life is-
sues. According to the World Health Organization (WHO),
up to 40 % of the population aged >70 years suffers from
OA, with 80 % of patients having some form of movement
limitation and 25 % having problems in performing their
daily activities [1].
Studies show that pain is an important cause of dis-
ability and reduced function in OA patients [2, 3]. Para-
cetamol and non-steroidal anti-inflammatory drugs
(NSAIDs) are the mainstay of pharmacological manage-
ment for controlling pain and stiffness in OA [4]. Oral
NSAIDs are recommended in patients who do not re-
spond to full-dose paracetamol. However, NSAIDs are
associated with adverse effects on the gastrointestinal
(GI), cardiovascular (CV) and renal systems. Further-
more, the risk of GI bleeding increases with age, and in
subjects with stomach ulcers and bleeding problems [5].
Some cyclooxygenase (COX)-2 inhibitors such as cele-
coxib are associated with less GI and CV adverse reac-
tions than non-selective NSAIDs (ns-NSAIDs) [5].
To reduce the risk of GI toxicity, the 2008 National
Institute for Health and Care Excellence (NICE) Clinical
Guideline for managing OA in adults recommends co-
prescribing both selective and ns-NSAIDs with proton-
pump inhibitors (PPIs) [5]. Celecoxib versus Omeprazole
aNd Diclofenac in patients with Osteoarthritis and
Rheumatoid arthritis (CONDOR) was a landmark trial
that was published after the NICE Clinical Guideline. It
showed that the proportion of patients developing clinic-
ally significant GI events throughout the GI tract was
significantly lower among those receiving celecoxib ver-
sus the ns-NSAID diclofenac plus omeprazole (hazard
ratio [HR], 4.3 in favour of celecoxib; 95 % confidence
interval [CI], 2.6 to 7.0; p < 0.0001) [6].
According to the NICE Clinical Guideline for managing
OA in adults, the choice of NSAID and PPI should be de-
termined by the cost of these agents [5]. A health eco-
nomic model developed by NICE demonstrated that
treatment with celecoxib plus PPI was more cost-effective
than that with diclofenac plus PPI [5]. Furthermore, it has
been shown that it is cost effective to co-prescribe a PPI
with a COX-2 inhibitor even in patients who have low risk
of GI adverse events [5, 7].
There are sparse data on the epidemiology of OA in
Saudi Arabia. A study conducted in 1995 among 5,894
Saudi Arabian adults found OA in 13 % of the subjects.
In line with global data, the prevalence of OA was high
in the elderly population (30.8 % in those aged 46–55
years and 60.6 % in those aged 66–75 years) [8]. Another
recent study found that elderly Saudi patients with OA
had significantly higher pain scores and physical disabil-
ity than those without OA, leading to a negative impacton their quality of life [9]. Clearly, there is an important
role for pain medications in the management of OA in
Saudi Arabia.
The Saudi Ministry of Health is the major government
provider and financer of healthcare services in Saudi
Arabia, responsible for 60 % of the total health services
in the country; other government bodies, including spe-
cialist referral hospitals, security forces and army med-
ical services, and school health units of the Ministry of
Education, account for another 20 % [10]. Private sector
healthcare services make up the remaining 20 %, import-
ant particularly in cities and large towns. As services in
government facilities are provided free-of-charge, a consid-
erable cost pressure is exerted on the national government
[10]. This prompted the establishment of a cooperative
health insurance scheme in 1999. Cooperative health insur-
ance is applicable to Saudi citizens and expatriates in the
private sector, in which employers are mandated to pay for
employees’ health coverage costs [10]. From one insurance
company in 2004, the providers of cooperative health in-
surance now number 25 companies.
Data on the cost effectiveness of drugs for OA will be in-
valuable to health policy makers, insurance providers and
healthcare professionals, allowing better informed decision-
making when choosing treatments to fund or utilize.
The objective of this study was to determine the cost
effectiveness of celecoxib versus ns-NSAIDs, with and
without PPI co-therapy, for managing OA in subjects
aged ≥65 years in Saudi Arabia.
Methods
This cost effectiveness analysis (CEA) was performed ac-
cording to the recommendations described by NICE
[11]. The primary outcome of cost effectiveness was
quality-adjusted life years (QALYs). A patient perspective
was adopted for the analysis as cost of treatment is
borne by patients in Saudi Arabia.
Comparators
Data from five large randomized controlled trials that re-
port GI and CV events associated with NSAID use in pre-
dominantly OA patients were used to obtain adverse event
data for this analysis. These included Celecoxib Long-term
Arthritis Safety Study (CLASS; celecoxib, ibuprofen and
diclofenac) [12], the Multinational Etoricoxib and Diclofe-
nac Arthritis Long-term study (MEDAL; etoricoxib and
diclofenac) [13], the Therapeutic Arthritis Research and
Gastrointestinal Event Trial (TARGET; lumiracoxib, na-
proxen and ibuprofen) [14, 15], the Etoricoxib versus
Diclofenac Sodium Gastrointestinal Tolerability and Effect-
iveness trial (EDGE; etoricoxib and diclofenac) [16] and
CONDOR [6]. Of these, CLASS and MEDAL also included
some patients with rheumatoid arthritis (RA). However,
the relative risk of adverse events was considered to be
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to suggest that rates of drug-induced adverse events are re-
lated to the type of arthritis [7]. These studies permit com-
parison between COX-2 inhibitors (celecoxib and
etoricoxib) and ns-NSAIDs (diclofenac, ibuprofen and na-
proxen). In this CEA, we compared the cost effectiveness
of celecoxib (200 mg OD) versus ibuprofen (400 mg TID),
diclofenac (50 mg TID), and etoricoxib (30 mg OD), with
and without omeprazole co-therapy (20 mg OD). These
NSAIDs were chosen as there are enough data from clin-
ical studies to allow reliable comparisons. Furthermore,
these are the most commonly used agents for treating OA
in Saudi Arabia [17]. Paracetamol was not included in the
analysis as it is considered to have inferior efficacy com-
pared with NSAIDs [18] and, thus, rarely used for man-
aging pain in Saudi OA patients.
Model design
The CEA health model has been described elsewhere
[11]. As such, the NICE health economic model devel-
oped in 2008 and updated by Brereton et al. with rela-
tive risk data for adverse events from the CONDOR trial
was adapted for this CEA [19]. It is in the form of a
Markov model with a 3-month cycle, which assumes
that each patient experiences only one GI or CV event
per cycle; patients may experience multiple GI and CV
events over the whole time horizon (Fig. 1). Treatment
duration of 6 months was adopted in the base case ver-
sion of the model. The possible adverse events consid-
ered by the model included GI symptoms, symptomaticFig. 1 Simplified version of the cost-effectiveness model structure. OA, osteulcer, complicated GI events, stroke, myocardial infarction
and heart failure. Patients could experience multiple
events at multiple points in time. The authors had previ-
ously utilized this model to evaluate the cost-effectiveness
of celecoxib versus ns-NSAIDs plus PPI for treating OA
in Algeria [20].
Patient populations
The model estimated results for patients with OA
aged ≥65 years. This age group was selected based on
the data suggesting a 2.96-times greater risk of develop-
ing a symptomatic or complicated GI event in subjects
aged ≥65 years [21].
Adverse events
Adverse event data were derived from the CLASS, MEDAL,
TARGET, EDGE and CONDOR studies [6, 12–16, 19, 20].
Dose adjustments were performed in accordance with
dosing regimens followed in Saudi Arabia. The overall
rates of adverse events observed with different NSAIDs in
these studies are shown in Table 1. Data from this table
were used to perform probabilistic sensitivity analyses.
Data for relative risk for each adverse event were taken
from the Brereton study, which pooled data from the
CLASS and CONDOR studies (Fig. 2) [19].
Costs
The analysis included costs incurred by patients for drug
acquisition, treatment of adverse events and physician
visits. The costs of treating adverse events included thoseoarthritis
Table 1 Overall rates of adverse events observed in CONDOR, MEDAL, CLASS, EDGE and TARGET [6, 11–15]
Treatment
options
Overall rates of adverse events/patient (% ± SD)
GI symptoms Symptomatic ulcer Complicated GI event Myocardial infarction Stroke Heart failure
Diclofenac 21.30 (±0.9) 0.14 (±0.02) 0.07 (±0.01) 0.09 (±0.01) 0.06 (±0.01) 0.02 (±0.01)
Ibuprofen 12.72 (±0.54) 0.20 (±0.09) 0.08 ((±0.04) 0.15 (±0.11) 0.06 (±0.04) 0.09 (±0.12)
Celecoxib 12.45 (±0.46) 0.09 (±0.04) 0.05 (±0.03) 0.15 (±0.10) 0.02 (±0.02) 0.04 (±0.06)
Etoricoxib 10.40 (±0.43) 0.14 (±0.02) 0.05 (±0.03) 0.10 (±0.01) 0.06 (±0.01) 0.02 (±0.01)
GI, gastrointestinal; SD, standard deviation
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consultations, and co-prescription of PPIs (Table 2). These
were estimated from data collected in July 2012 from
seven private hospitals in Jeddah, Saudi Arabia. Daily
treatment costs of drugs were obtained from the Saudi
Ministry of Health drug list 2013 (Table 3) [22].
It was assumed that patients made one consultation
per adverse event, with patients with dyspepsia or symp-
tomatic ulcer needing outpatient management only.
Hospitalization costs were estimated in patients with
complicated GI event, myocardial infarction, stroke and
heart failure; the duration of hospitalization was based
on the type and severity of the adverse event.
Costs were estimated for treatment over a period of
6 months, 2 years and 5 years. All daily cost data were
expressed in 2013 prices and converted to US$ using an
average 2013 exchange rate (1 US$ = 3.75 Saudi Riyal). A
discount rate of 3 % was used for costs and benefits, in
line with the WHO guide for conducting a CEA [23].
QALY data
The utility scores were taken from the EQ-5D and Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) scores used in the NICE economic model [7].Fig. 2 Relative risks for adverse events according to estimated treatment eEQ-5D is a standardized instrument used to measure
health outcomes while WOMAC is a 24-item instrument
validated for assessing pain, stiffness, and physical function
in OA patients, widely used for evaluating outcomes in OA
clinical trials. There was no evidence to suggest any correl-
ation between different drug doses and drug efficacy. Thus,
for this study, equal utility weights were assumed for ns-
NSAIDs and COX-2 inhibitors in patients who did not ex-
perience adverse events. Utility weights for adverse events
were based on data from the literature [24, 25].
Cost-effectiveness analyses
The expected costs and QALY gains associated with eight
treatment options were calculated for treatment administered
over 6 months, 2 years and 5 years using deterministic ana-
lysis. Incremental cost effectiveness ratios (ICERs), defined as
the additional cost per patient achieving a unit of effective-
ness compared with the next less costly, non-dominated op-
tion, were calculated for each treatment duration.
Sensitivity analyses
To assess the robustness of the model, probabilistic sen-
sitivity analysis was performed using Monte Carlo simu-
lations by generating 10,000 second-order iterations offfects [18]. GI, gastrointestinal
Table 2 Costs of managing specific adverse events in selected hospitals in Jeddah, Saudi Arabia
Cost of management (US $) International Medical Center Abu Zenada Hospital Al Hayat Hospital Khalid Idris Center Al Jedaani Hospital
Dyspepsia 53.33 53.33 80.00 533.33 53.33
Symptomatic ulcer 800.00 346.67 346.67 666.67 320.00
Complicated GI event 2,680.53 1,066.67 213.33 800.00 400.00
Myocardial infarction 1,200.00 1,866.67 426.67 1,066.67 2,000.00
Stroke 2,133.33 1,866.67 426.67 1,066.67 2,000.00
Heart failure 2,133.33 1,733.33 426.67 1,066.67 2,000.00
*1 US$ = 3.75 Saudi Riyal in 2013.
Patients with dyspepsia or symptomatic ulcer were assumed to need outpatient management only.
Hospitalization costs were estimated for patients with a complicated GI event, myocardial infarction, stroke and heart failure.
Costs for managing specific adverse events were not available for United Doctors Hospital and Hai Al Jameaa Hospital.
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was used for the parameters selected for the analysis.
The 10,000 iterations generated costs and QALY results
which were used to construct a cost-effectiveness accept-
ability curve (CEAC) that summarized the evidence in
favour of a treatment arm versus comparators, and dem-
onstrated the confidence with ICERs obtained over a
range of thresholds of acceptability.
Results
Base case analysis
Base case analysis showed that the estimated QALY gain
per patient was highest with celecoxib plus PPI (0.40)
followed by etoricoxib plus PPI (0.38) and celecoxib
alone (0.37) versus all comparators. The expected cost of
treatment per patient was lowest with ibuprofen plus
PPI (US$ 1,314.50), followed by celecoxib plus PPI (US$
1,422.80) and celecoxib (US$ 1,543.50) (Table 4).
The most cost effective treatment over a 6-month
period was celecoxib plus PPI, with an incremental cost
of US$ 108.30 and an incremental QALY gain of 0.06
resulting in an ICER of US$ 1,805.00 versus ibuprofen
plus PPI (Table 4). When celecoxib plus PPI was ex-
cluded from the base case analysis, celecoxib alone was
the most cost effective intervention, with an incremental
cost of US$ 229.00 and an incremental QALY gain of
0.03 giving an ICER of US$ 7,633.33 versus ibuprofen
plus PPI (data not shown).
The ICERs for both celecoxib alone and celecoxib plus
PPI are <1 gross domestic product (GDP) per capita inTable 3 Daily costs of NSAIDs in Saudi Arabia [21]
Drug and dose Cost/day (US$)*
Diclofenac 50 mg TID 1.16
Celecoxib 200 mg OD 0.83
Ibuprofen 400 mg TID 0.49
Omeprazole 20 mg OD 1.23
Etoricoxib 60 mg OD 1.63
NSAIDs, non-steroidal anti-inflammatory drugs
*1 US$ = 3.75 Saudi Riyal in 2013Saudi Arabia in 2013 (US$ 25,961) [26], and thus consid-
ered very cost effective by the WHO-established Commis-
sion on Macroeconomics and Health [27]. Thus, celecoxib
alone and celecoxib plus PPI are very cost effective treat-
ments for Saudi Arabian OA subjects aged ≥65 years.
The other treatment options were either more expen-
sive or less effective and, therefore, excluded by simple
dominance.
Sensitivity analyses
Analyses over 2- and 5-year treatment durations found
that celecoxib plus PPI and celecoxib alone were consist-
ently associated with higher incremental QALY gain per
patient and decreasing ICERs versus comparators. More-
over, ICERs associated with celecoxib plus PPI remained
lower than those of comparators across all treatment du-
rations, making it the most cost-effective intervention
for medium- and long-term use in elderly OA patients
in Saudi Arabia (Tables 4, 5 and 6).
When celecoxib plus PPI was excluded from the ana-
lysis, celecoxib alone was the most cost effective option
for treating OA in Saudi Arabia over all treatment dura-
tions (data not shown). Over 2- and 5-year treatment
durations, the increased costs per patient with celecoxib
alone (US$ 4,716.80 and US$ 7,407.10, respectively) were
associated with highest QALYs gained per patient versus
all comparators (1.24 QALYs and 2.50 QALYs, respect-
ively), giving ICERs of US$ 3,943.85 and US$ 2,096.32,
respectively, versus ibuprofen plus PPI (data not shown).
We believe this is an important finding relevant for con-
sideration in situations where PPIs may not be available.
Of note, the ICERs for long-term treatment with cele-
coxib plus PPI and celecoxib alone were within the pre-
scribed 1 GDP per capita for Saudi Arabia.
The robustness of findings was further confirmed with
CEACs for the base case analysis. The probability that a
treatment option would be cost effective was plotted
against the Y-axis and the threshold cost effectiveness
(the amount of money that one is willing to spend to
gain one year of life) on the X-axis. Our analysis found a
significantly higher likelihood that celecoxib plus PPI
Table 4 Cost effectiveness analysis over 6-month treatment duration: Base case analysis
Therapy Cost/patient (US$) QALYs gained/patient ICER (ΔC/ΔE) Comparator
Ibuprofen + PPI 1,314.50 0.34 3,866.18 No treatment
Celecoxib + PPI 1,422.80 0.40 1,805.00 Ibuprofen + PPI
Celecoxib* 1,543.50 0.37 Dominated -
Diclofenac + PPI* 1,565.30 0.35 Dominated -
Ibuprofen* 1,608.20 0.28 Dominated -
Diclofenac* 1,695.00 0.31 Dominated -
Etoricoxib + PPI 1,749.00 0.38 Dominated -
Etoricoxib 1,839.10 0.36 Dominated -
*Simple dominance: Another option is less expensive and more effective
ICER, incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality-adjusted life year
ICER: additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option
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comparators once the willingness to pay is over US$
2,000.00 (data not shown).
Discussion
After considering adverse event data from five large tri-
als including predominantly OA patients, this CEA
found that, over a 6-month treatment duration, cele-
coxib is more cost-effective than ns-NSAIDs, with and
without PPI co-therapy, for treating Saudi Arabian OA
patients aged ≥65 years. Celecoxib plus PPI remained
the most cost-effective intervention even over a 5-year
treatment duration. Analyses over 6-month, 2-year and
5-year treatment durations found that, next to celecoxib
plus PPI, celecoxib alone had the highest QALYs gained/
patient and was the most cost effective intervention. At
a cost effectiveness threshold of 1 GDP per capita in
Saudi Arabia, celecoxib plus PPI, as well as celecoxib
alone, were highly cost effective for medium- and long-
term treatment of OA in elderly Saudi Arabian patients.
Two recent economic analyses used the same eco-
nomic model and clinical data and arrived at conclusionsTable 5 Cost effectiveness analysis over 2-year treatment duration
Therapy Cost/patient (US$) QALYs ga
Ibuprofen + PPI 4,204.10 1
Celecoxib + PPI 4,512.80 1
Celecoxib* 4,716.80 1
Diclofenac + PPI* 4,891.60 1
Ibuprofen* 5,575.10 0
Diclofenac* 5,662.50 0
Etoricoxib + PPI 5,892.40 1
Etoricoxib 6,621.80 1
*Simple dominance: Another option is less expensive and more effective
ICER, incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality
ICER: additional cost per patient achieving a unit of effectiveness compared with ththat align with our findings. A recent CEA performed in
Algeria found that celecoxib plus PPI and celecoxib
alone were associated with the highest QALYs gained
per patient versus ns-NSAIDs with and without PPI co-
therapy over 6-month and 5-year time horizons. The au-
thors concluded that these were the most cost effective
treatments for elderly OA patients in Algeria [20]. Simi-
larly, Brereton et al. also showed that celecoxib plus PPI
was more cost effective than diclofenac plus PPI for
treating OA in the UK [19].
Could these results not have been extrapolated to the
Saudi Arabian setting? Indeed, OA management varies
very minimally across countries – physicians in the Mid-
dle East follow the same international treatment guide-
lines as doctors in Europe, and patients will present, on
average, the same responses to treatment; this is why we
decided to use the NICE health economic model for this
CEA, the structure of which corresponds specifically to
the management of OA patients. However, it would have
been inaccurate to extrapolate Algerian or UK economic
model outcomes to the Saudi Arabian setting as prices,
treatment costs, treatment pathways, and other variablesined/patient ICER (ΔC/ΔE) Comparator
.11 3,787.48 No treatment








e next less costly, non-dominated option
Table 6 Cost effectiveness analysis over 5-year treatment duration
Therapy Cost/patient (US$) QALYs gained/patient ICER (ΔC/ΔE) Comparator
Celecoxib + PPI 6,705.80 2.68 2,502.16 No treatment
Ibuprofen + PPI* 7,008.80 2.31 Dominated -
Celecoxib* 7,407.10 2.50 Dominated -
Diclofenac + PPI* 7,930.50 2.39 Dominated -
Diclofenac* 10,140.20 2.05 Dominated -
Ibuprofen* 10,586.10 1.83 Dominated -
Etoricoxib + PPI 11,574.20 2.64 Dominated -
Etoricoxib 12,983.90 2.48 Dominated -
*Simple dominance: Another option is less expensive and more effective
ICER, incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality-adjusted life year
ICER: additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option
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Saudi Arabia and, to our knowledge, cannot be obtained
from other published sources.
The findings of this CEA are in agreement with several
economic analyses that show celecoxib to be more cost
effective than ns-NSAIDs given with and without gastro-
protective agents to patients with OA and RA [28–33].
Two economic analyses performed in Hong Kong found
celecoxib to be more cost-effective than ns-NSAIDs with
or without PPI co-therapy in OA and RA subjects with
high GI risk [29, 32]. According to Latimer et al., co-
prescription of PPI with a COX-2 inhibitor rather than
with an ns-NSAID was cost effective even in young sub-
jects who have low GI risk [7]. In another study,
Zabinski et al. found that co-prescription of ns-NSAIDs
with gastroprotective agents was cost effective in high-
risk patients, and the benefits accrued by using celecoxib
in moderate-to-high risk patients served to offset the
high costs of using celecoxib to treat low-risk patients
[33]. However, this finding may be more relevant in
health systems where the cost of treatment is borne by
the government rather than patients.
This study has several strengths. Unlike most studies
that restricted the analysis to a treatment period of
6 months, we estimated costs and benefits over 5 years of
treatment. This is very relevant in OA as it is a chronic
disease for which patients need long-term NSAID treat-
ment, resulting in cumulative risk of NSAID-induced
gastropathy [30]. Notably, in this model, patients with pre-
vious events were considered to have a higher likelihood
of presenting with new events. Celecoxib plus PPI was the
most cost effective intervention despite considering CV
adverse events such as myocardial infarction, stroke and
heart failure in the analysis. This is an important consider-
ation as the elderly population included in this study may
also be suffering from comorbid CV conditions. Further-
more, they may also be on prophylactic aspirin, though we
did not model the increased risk of bleeding arising from
aspirin therapy in this analysis. Thus, the incrementalbenefits from celecoxib plus PPI may well be underesti-
mated in the current analysis.
This analysis also has several limitations. We did not
stratify the estimated costs and benefits according to the
age or risk category of patients. Loyd et al. found that
the ICERs decreased when their analysis considered the
increased risk of peptic ulcer bleeding with advancing
age [30]. This analysis did not consider the indirect costs
of OA which are known to be significant and compar-
able with direct costs [34]. Adverse event data were
pooled from five randomized controlled trials rather
than real-life situations; however, these were large stud-
ies conducted in multiple centres across several coun-
tries, and may, therefore, be considered to reflect real-
life incidence of adverse events.
Some limitations are related to the economic model used
for the analysis, which may have underestimated the poten-
tial benefits of treatment. For example, the model assumed
that patients were maintained on the same treatment
throughout the study period, whereas, in reality, patients
often switch treatments due to lack of efficacy or drug in-
tolerance. In addition, the model assumed continuous use
of a drug when intermittent NSAID treatments are also
known to be effective for some OA patients [30]. Only dif-
ferences in GI and CV adverse event rates were modelled,
with no consideration of the costs arising from any possible
differences in effectiveness of the different treatments. Of
note, the differences in adverse event rates derived from the
randomized controlled trials were small, introducing an
element of uncertainty to the sensitivity analyses.
Conclusions
After considering new adverse risks, this CEA found that
celecoxib plus PPI and celecoxib alone are very cost effect-
ive options for Saudi Arabian OA patients aged ≥65 years.
Celecoxib plus PPI was the most dominant treatment over
6-month and 5-year periods, making it the most cost-
effective option for medium- and long-term management
of elderly OA patients in Saudi Arabia.
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